See more : Draganfly Inc. (DPRO) Income Statement Analysis – Financial Results
Complete financial analysis of Royalty Pharma plc (RPRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Royalty Pharma plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bangkok Dusit Medical Services Public Company Limited (BDMS-R.BK) Income Statement Analysis – Financial Results
- Eledon Pharmaceuticals, Inc. (ELDN) Income Statement Analysis – Financial Results
- Sparindex INDEX Nye Obl.mark Ak (SPVINOAKKKLA.CO) Income Statement Analysis – Financial Results
- Everdisplay Optronics (Shanghai) Co., Ltd. (688538.SS) Income Statement Analysis – Financial Results
- Beijing Beida Jade Bird Universal Sci-Tech Company Limited (8095.HK) Income Statement Analysis – Financial Results
Royalty Pharma plc (RPRX)
About Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.35B | 2.24B | 2.29B | 2.12B | 1.81B | 1.79B | 1.60B | 1.88B | 1.65B |
| Cost of Revenue | 560.66M | 5.67M | 23.00M | 88.11M | 1.02B | 135.96M | 33.27M | 0.00 | 0.00 |
| Gross Profit | 1.79B | 2.23B | 2.27B | 2.03B | 794.93M | 1.66B | 1.56B | 1.88B | 1.65B |
| Gross Profit Ratio | 76.19% | 99.75% | 99.00% | 95.85% | 43.82% | 92.43% | 97.92% | 100.00% | 100.00% |
| Research & Development | 52.00M | 177.11M | 200.08M | 26.00M | 83.04M | 392.61M | 117.87M | 91.02M | 98.38M |
| General & Administrative | 249.75M | 227.30M | 182.83M | 182.00M | 103.44M | 61.91M | 106.44M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 249.75M | 227.30M | 182.83M | 182.00M | 103.44M | 61.91M | 106.44M | 69.51M | 121.42M |
| Other Expenses | 560.66M | 909.91M | 475.84M | 319.00M | -995.40M | -1.52M | -1.62M | -925.80M | -570.18M |
| Operating Expenses | 862.40M | 1.31B | 858.75M | 527.00M | -808.92M | 430.45M | 658.24M | 1.09B | 789.98M |
| Cost & Expenses | 862.40M | 1.31B | 858.75M | 527.00M | -808.92M | 430.45M | 658.24M | 1.15B | 858.14M |
| Interest Income | 72.29M | 78.34M | 53.54M | 28.38M | 22.33M | 24.44M | 6.76M | 0.00 | 0.00 |
| Interest Expense | 187.19M | 187.96M | 166.14M | 157.00M | 268.57M | 279.96M | 247.34M | 238.92M | 224.42M |
| Depreciation & Amortization | 395.13M | 5.67M | 23.00M | 23.06M | 23.92M | 33.27M | 33.27M | 68.20M | 68.16M |
| EBITDA | 1.89B | 928.56M | 1.45B | 1.68B | 2.65B | 1.40B | 972.96M | 1.07B | 862.44M |
| EBITDA Ratio | 80.15% | 43.95% | 64.73% | 88.69% | 145.37% | 78.76% | 71.46% | 42.14% | 52.19% |
| Operating Income | 1.49B | 977.50M | 1.43B | 1.60B | 2.62B | 1.36B | 939.69M | 722.87M | 794.28M |
| Operating Income Ratio | 63.37% | 43.69% | 62.49% | 75.16% | 144.59% | 76.02% | 58.81% | 38.50% | 48.07% |
| Total Other Income/Expenses | 207.94M | -77.00M | -189.51M | 106.56M | -161.76M | 153.41M | 403.49M | 39.02M | -35.57M |
| Income Before Tax | 1.70B | 230.06M | 1.24B | 1.70B | 2.46B | 1.52B | 1.34B | 761.90M | 758.71M |
| Income Before Tax Ratio | 72.20% | 10.28% | 54.21% | 80.21% | 135.67% | 84.57% | 84.06% | 40.58% | 45.91% |
| Income Tax Expense | 0.00 | 187.23M | 762.45M | 1.15B | 349.33M | 433.37M | 542.66M | 195.99M | 177.28M |
| Net Income | 1.13B | 42.83M | 478.75M | 495.20M | 2.35B | 1.38B | 1.21B | 565.91M | 581.43M |
| Net Income Ratio | 48.20% | 1.91% | 20.91% | 23.34% | 129.45% | 76.76% | 75.72% | 30.14% | 35.19% |
| EPS | 3.41 | 0.10 | 1.15 | 1.32 | 6.42 | 3.89 | 3.42 | 0.93 | 0.96 |
| EPS Diluted | 2.53 | 0.10 | 1.15 | 1.32 | 6.42 | 3.89 | 3.42 | 0.93 | 0.96 |
| Weighted Avg Shares Out | 447.60M | 437.96M | 414.79M | 375.44M | 365.90M | 354.18M | 354.18M | 607.04M | 607.04M |
| Weighted Avg Shares Out (Dil) | 602.90M | 437.97M | 414.80M | 375.46M | 365.90M | 354.18M | 354.18M | 607.04M | 607.04M |
Royalty Pharma Declares Second Quarter 2024 Dividend
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2024 of $0.21 per Class A ordinary share.
3 Pharma Stocks to Sell in April Before They Crash & Burn
There are some pharma stocks to sell in April. Holding these companies is too risky, especially as the industry faces increasing regulatory scrutiny and pricing pressures.
Billionaire Bargain Bin: 3 Stocks the Forbes 400 Loves (That You've Never Heard Of)
The Forbes 400 is a list of America's 400 wealthiest people. Right now, to get on the coveted list, one's net worth has to be at least $2.9 billion.
April's Hidden Gems: 3 Overlooked Stocks to Freshen Up Your Portfolio
Today we dive deeper than the headlines to uncover overlooked stocks. In the artificial intelligence (AI) market of 2024, tech giants dominated the first quarter.
The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio
With the market trading near all-time highs, undervalued healthcare stocks offer a compelling opportunity. Fundamentally, the sector could benefit from a rotation in the innovation ecosystem.
Royalty Pharma to Present at TD Cowen's 44th Annual Health Care Conference
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen's 44th Annual Health Care Conference on March 5, 2024 at 10:30 a.m. ET.
Royalty Pharma (RPRX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Royalty Pharma (RPRX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street...
Wall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 Months
SLB expects strong growth in 2024. Alibaba stock is dirt cheap, and the company plans major buybacks over the next few years.
Royalty Pharma PLC (RPRX) Q4 2023 Earnings Call Transcript
Royalty Pharma PLC (RPRX) Q4 2023 Earnings Call Transcript
Royalty Pharma Reports Q4 and Full Year 2023 Results
NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year of 2023 and introduced full year 2024 guidance for Portfolio Receipts. “Royalty Pharma delivered outstanding results...
Source: https://incomestatements.info
Category: Stock Reports